Tresiba Geriatric (65+) Dosing: Insulin Degludec in Older Adults

Why Older Adults Require Special Consideration With Insulin Degludec

Aging changes how basal insulin behaves in the body and how patients tolerate dosing errors. Adults aged 65 and older have higher rates of renal function decline, polypharmacy, cognitive impairment, and fall risk, all of which amplify the consequences of hypoglycemia. The FDA prescribing information for Tresiba specifically states that older patients may be at higher risk for adverse reactions and that dose selection should be conservative.

Physiological Changes That Alter Insulin Pharmacodynamics

Reduced glomerular filtration rate slows insulin clearance, which can extend the effective duration of each dose. Body composition shifts toward higher fat mass and lower lean mass, altering subcutaneous absorption. Counterregulatory hormone responses, particularly glucagon and epinephrine, are blunted with age, meaning hypoglycemia may be less symptomatic until it is already severe [1].

Hepatic glucose output also declines in older adults, reducing the baseline glucose contribution that higher insulin doses are meant to offset. Taken together, these changes mean that the same unit-per-kilogram dose produces a greater glucose-lowering effect in a 72-year-old than in a 45-year-old.

Cognitive and Functional Barriers to Safe Self-Management

A 2019 analysis published in Diabetes Care found that approximately 18% of Medicare beneficiaries with insulin-treated diabetes had cognitive impairment severe enough to affect self-management [2]. Patients who cannot reliably remember whether they injected their dose are at high risk for double-dosing. Degludec's flat pharmacokinetic profile and long half-life of approximately 25 hours provide some buffer compared with peaking insulins, but no basal insulin is fully protective against dosing errors.

Dexterity limitations affect the ability to draw up and inject correct volumes. The Tresiba FlexTouch pen is pre-filled and dose-step verified by an audible click, which can support accuracy in patients with mild hand tremor [3].

FDA-Approved Dosing Recommendations for Adults 65 and Older

The FDA label for insulin degludec does not specify a geriatric-specific starting dose, but it does state that conservative initial dosing and titration are warranted [3]. Clinical guidelines provide more granular targets.

Starting Dose in Insulin-Naive Patients

For an older adult starting basal insulin for the first time, the ADA Standards of Medical Care in Diabetes 2024 recommends initiating at 10 units once daily or 0.1 to 0.2 units/kg/day, whichever is lower [4]. For a 70 kg patient, that range is 7 to 14 units; selecting the lower end (7 to 10 units) is appropriate when the patient is frail, has an eGFR below 45 mL/min/1.73 m², or is on other agents that increase hypoglycemia risk such as sulfonylureas.

The American Association of Clinical Endocrinology (AACE) 2022 consensus statement on insulin management recommends starting at 0.1 units/kg in patients 65 and older when transitioning from oral agents alone [5].

Titration Protocol in Older Adults

Standard degludec titration adjusts the dose by 2 units every 3 days based on fasting glucose readings. In adults 65 and older, many geriatric diabetes specialists extend that interval to every 3 to 4 days and limit upward adjustments to 2 units at a time rather than the 2 to 4 units used in younger adults. This slower pace reduces the risk of stacking dose increases before the pharmacokinetic steady state, which degludec reaches in approximately 3 to 4 days [3].

The titration target for most older adults is a fasting glucose of 80 to 130 mg/dL. For patients who are frail, have a life expectancy below 5 years, or have a history of severe hypoglycemia, a target of 100 to 150 mg/dL is more appropriate [4].

Switching From Another Basal Insulin

When converting from glargine U-100 or detemir to degludec in an older patient, a unit-to-unit conversion is acceptable as a starting point, but some clinicians reduce the initial degludec dose by 10 to 20% in patients with suboptimal renal function or recent hypoglycemic episodes. The FDA label notes that dose adjustments may be needed when switching insulin products [3].

Converting from NPH insulin requires a more significant reduction. Because NPH peaks at 4 to 8 hours while degludec is effectively peakless, the glycemic effect is distributed differently across the day, and titration must start from a conservative base.

DEVOTE Trial: Key Evidence for Older Patients

DEVOTE (N=7,637) was a double-blind, treat-to-target cardiovascular outcomes trial comparing insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Results were published in the New England Journal of Medicine in 2017 [6].

Cardiovascular Outcomes

Degludec was non-inferior to glargine U-100 for the primary composite endpoint of major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. The rate ratio was 0.91 (95% CI 0.78 to 1.06) [6]. This confirmed that older patients with established cardiovascular disease can use degludec without increased cardiac risk.

Hypoglycemia Results

Confirmed symptomatic hypoglycemia (blood glucose <56 mg/dL or severe) occurred at a rate ratio of 0.83 (95% CI 0.75 to 0.92, P<0.001) favoring degludec [6]. Nocturnal confirmed symptomatic hypoglycemia was reduced by 27% compared with glargine U-100 (rate ratio 0.73, 95% CI 0.60 to 0.89, P<0.001) [6]. Nocturnal hypoglycemia is especially dangerous in older adults because it may not awaken the patient, and falls during nighttime bathroom visits are a common injury mechanism.

Pre-Specified Subgroup: Patients 65 and Older

The DEVOTE investigators reported that hypoglycemia benefits were consistent across age subgroups. Patients aged 65 and older, who represented approximately 45% of the DEVOTE population, showed directionally similar or greater reductions in nocturnal hypoglycemia with degludec relative to glargine [6]. This subgroup consistency is one reason many geriatricians favor degludec over glargine U-100 when basal insulin is clinically necessary in an older patient.

Renal Impairment Considerations in Geriatric Patients

Chronic kidney disease (CKD) is present in approximately 38% of adults with diabetes aged 65 and older [7]. Reduced eGFR affects insulin clearance and the activity of many concomitant oral glucose-lowering agents, compounding hypoglycemia risk.

FDA Label Guidance on Renal Impairment

The FDA prescribing information states that insulin degludec has not been studied in patients with renal impairment but, as with all insulins, more frequent glucose monitoring and dose adjustments may be required [3]. There is no specific dose reduction formula tied to eGFR levels; the recommendation is increased monitoring rather than a fixed percentage reduction.

When eGFR falls below 30 mL/min/1.73 m², many clinicians reduce the total daily basal insulin dose by 25 to 50% from the current maintenance dose and re-titrate upward only if fasting readings consistently exceed the individualized target. This approach aligns with guidance from the National Kidney Foundation [8].

Metformin and SGLT2 Inhibitor Interactions

Metformin is generally discontinued when eGFR drops below 30 mL/min/1.73 m² [4], which can remove its insulin-sparing effect and require a modest upward insulin adjustment. Conversely, adding an SGLT2 inhibitor at eGFR 45 or above may reduce insulin requirements by 10 to 15%, necessitating a proactive dose reduction to prevent hypoglycemia [4].

Sulfonylureas, which are still prescribed in many older patients, increase hypoglycemia risk when combined with basal insulin. The ADA and AACE both recommend discontinuing or down-titrating the sulfonylurea before initiating basal insulin rather than simply adding insulin on top [4,5].

Hypoglycemia Risk Management in Adults 65 and Older

Hypoglycemia in older adults carries consequences beyond the episode itself. A severe event requiring assistance is associated with a 2.5-fold increase in dementia risk in some retrospective analyses [9]. Falls during hypoglycemic episodes account for a substantial portion of hip fractures in insulin-treated older adults [10].

Identifying High-Risk Older Patients Before Titrating

Before any upward dose adjustment, assess for:

• Fasting glucose readings already at or below 100 mg/dL
• Recent symptomatic hypoglycemia in the prior 30 days
• eGFR below 45 mL/min/1.73 m²
• Concomitant use of a sulfonylurea, meglitinide, or high-dose alcohol
• Cognitive impairment affecting ability to recognize symptoms
• Living alone or limited access to glucagon rescue

Any two or more of these factors should prompt holding titration and reassessing the HbA1c target.

Continuous and Flash Glucose Monitoring in Older Adults

The ADA 2024 Standards state that continuous glucose monitoring (CGM) should be offered to all adults using insulin, including those aged 65 and older [4]. CGM devices that alert patients and caregivers to nocturnal lows are particularly well-suited to older patients on degludec, since the long half-life means that a downward glucose trend during the night may persist for several hours without correction.

A practical framework used by the HealthRX clinical team stratifies older patients on degludec into three titration tiers based on functional status: (1) functionally independent with HbA1c target 7.0 to 7.5%, standard 2-unit titration every 3 days; (2) functionally dependent or mild cognitive impairment with HbA1c target 7.5 to 8.0%, 1-unit titration every 4 days and caregiver involvement required; (3) frail or limited life expectancy with HbA1c target 8.0 to 8.5%, no further titration unless symptomatic hyperglycemia is present, and active deprescribing review every 6 months.

Glucagon Rescue Availability

All patients or their caregivers should have a glucagon rescue kit at home. Nasal glucagon (Baqsimi) and auto-injector glucagon (Gvoke) are easier for older patients or caregivers to administer correctly compared with the older reconstitution kits [11]. The prescription for glucagon should be renewed alongside the insulin prescription at every visit.

HbA1c Targets in Older Adults on Degludec

The ADA 2024 Standards of Medical Care include a dedicated section on older adults with diabetes, recommending HbA1c targets individualized by functional status, cognitive status, and life expectancy [4]. The American Geriatrics Society Beers Criteria flags insulin as a high-risk medication in older adults specifically due to hypoglycemia risk, which supports liberal HbA1c targets in frail patients [12].

ADA Tiered Targets for Adults 65 and Older

• Healthy, few coexisting conditions, intact cognition: HbA1c <7.0 to 7.5%
• Complex/intermediate health: HbA1c <8.0%
• Very complex/poor health: HbA1c <8.5% (avoiding hypoglycemia more important than tight control)

These targets do not change because the patient is on degludec specifically. They apply to all basal insulin regimens in this age group. Degludec's lower nocturnal hypoglycemia rate means that a target of 7.5% may be achievable with less overnight risk compared with glargine U-100, but the target itself is still driven by functional status.

Time in Range as a Complementary Metric

For older patients using CGM, time in range (TIR, defined as 70 to 180 mg/dL) of 50% or greater is an acceptable goal when HbA1c is 7.0 to 8.0%. Time below range (TBR, <70 mg/dL) should remain below 4% of sensor readings, and time below 54 mg/dL should remain below 1% [4].

Drug-Drug Interactions Relevant to Older Patients on Degludec

Older adults take an average of 5 to 7 prescription medications [13]. Several drug classes commonly used in geriatric patients either potentiate or attenuate insulin's glucose-lowering effect.

Agents That Increase Hypoglycemia Risk

Beta-blockers (commonly used for hypertension and heart failure) can mask tachycardia, a key hypoglycemia warning sign, while leaving diaphoresis intact. ACE inhibitors may increase insulin sensitivity modestly. Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) can cause both hypoglycemia and hyperglycemia through beta-cell effects; short courses warrant closer glucose monitoring [3].

Alcohol use, even moderate, impairs hepatic gluconeogenesis and can extend the duration of insulin-induced hypoglycemia significantly. Asking about alcohol use specifically during insulin titration visits is warranted.

Agents That Reduce Insulin Efficacy

Corticosteroids are a frequent cause of insulin under-dosing in older inpatients and outpatients. Even a short course of prednisone 20 mg/day can raise fasting glucose by 30 to 60 mg/dL in an insulin-treated patient. A temporary 10 to 20% degludec dose increase, combined with close monitoring, is reasonable during steroid courses lasting 5 days or longer.

Atypical antipsychotics (olanzapine, quetiapine, risperidone) increase insulin resistance and are prescribed in a meaningful proportion of older patients for behavioral symptoms of dementia. Their initiation should trigger re-evaluation of the current degludec dose.

Deprescribing Insulin Degludec in Older Adults

Deprescribing is the planned reduction or stopping of a medication when the harms outweigh the benefits for a given patient. Insulin is one of the highest-priority medications for deprescribing review in frail older adults [12].

When to Consider Dose Reduction or Discontinuation

Consider reducing or stopping degludec when:

• Life expectancy is estimated at 5 years or fewer and HbA1c is below 8.5%
• Recurrent severe hypoglycemia (requiring third-party assistance) has occurred two or more times in 12 months
• The patient or family has explicitly prioritized quality of life and symptom management over glycemic targets
• Weight loss has led to markedly reduced insulin requirements and HbA1c is now below 7.0%
• Renal function has declined to an eGFR below 15 mL/min/1.73 m² and hypoglycemia is frequent

Tapering Protocol

Abrupt discontinuation of basal insulin risks symptomatic hyperglycemia, particularly in type 1 diabetes. In type 2 diabetes, a 10 to 20% dose reduction every 2 to 4 weeks, guided by fasting glucose and symptom review, is a reasonable approach. If fasting glucose remains below 130 mg/dL after each step-down, the reduction continues. If glucose rises above 180 mg/dL or the patient develops osmotic symptoms, the previous dose is restored and an alternative management plan is discussed.

The 2023 Canadian Diabetes Association position statement on deprescribing in older adults supports this graduated approach and emphasizes involving the patient, caregivers, and pharmacist in the decision [14].

Practical Administration Notes for Older Patients

Injection technique errors are more common in older adults. The FlexTouch pen for degludec delivers doses in 1-unit increments (U-100) or 2-unit increments (U-200). The U-200 concentration delivers the same number of units in half the injection volume, which may be preferred in patients requiring higher doses to reduce injection discomfort but is not appropriate for patients requiring doses below 20 units since the minimum dose is 2 units per injection.

Injection sites should be rotated within the same anatomical region (abdomen, thigh, or upper arm) each day to prevent lipohypertrophy, which impairs absorption and creates erratic glucose patterns [3]. The abdomen provides the most consistent subcutaneous layer in older adults with reduced thigh and arm muscle mass.

Storage of the in-use pen at room temperature (below 86°F / 30°C) for up to 56 days is acceptable. Unused pens should remain refrigerated at 36 to 46°F (2 to 8°C). Older patients living in warmer climates or with unreliable refrigeration should be counseled on proper storage explicitly [3].